Withaferin A Exerts Cytotoxicity in Single/Multidrug‐Resistant Gastric and Ovarian Cancer Cells and Tumor Xenografts Through the AKT–NF‐κB–STAT3–Survivin Axis
Molecular Carcinogenesis · 2025-12 · 64 (12) · 2037-2051
DOI: 10.1002/mc.70043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, online erschienen am 30.09.2025. Verfasst von Priti S Shenoy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Imaging Cell Signaling & Therapeutics Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India. Hauptthemen laut MEDLINE: Withanolides, Ovarian Neoplasms, Drug Resistance, Neoplasm, Stomach Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Resistance to primary chemotherapeutics poses a significant challenge in treating solid tumors. The majority of the second‐line chemo and targeted therapeutics act moderately/less effectively in drug‐resistant tumors owing to the multicausal nature of drug resistance. Therefore, a single agent with pleiotropic effects would be beneficial in combating this adversity. Withania somnifera exhibits multifunctional anticancer properties, but its role in overcoming chemoresistance remains poorly understood. We evaluated the cytotoxic effect of Ashwamax TM ‐ W. somnifera (WS)—extract and Withaferin A (WFA), in intrinsically resistant (KATO‐III and SKOV3) and acquired chemoresistant gastric (AGS 5FU ) and ovarian (A2780 LR ) cancer cellular models. We examined their impact on autophagy and apoptosis pathways and elucidated the underlying molecular mechanism. In vivo efficacy of WFA on cisplatin‐paclitaxel‐resistant epithelial ovarian cancer (EOC) xenografts was assessed using noninvasive optical imaging. Mechanistically, WFA is more proficient in targeting chemoresistant cells than Ashwamax TM ‐WS extract and activates apoptosis by overriding the AKT–NF‐κB–STAT3–survivin axis. Preclinical imaging revealed dose‐dependent tumor regression (during and after treatment) in platinum‐taxol‐resistant EOC xenografts that were unresponsive to cisplatin challenge. WFA, at 3 mg kg −1 dosage, reduced tumor volume by 4.7‐fold compared to controls, with sustained antitumor effects persisting after treatment cessation. WFA effectively targets the AKT–NF‐κB–STAT3–survivin axis to overcome single and multidrug resistance in gastric and epithelial ovarian cancers, presenting a promising therapeutic alternative for chemoresistant malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Imaging Cell Signaling & Therapeutics Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
- Homi Bhabha National Institute, Mumbai, India.
- Department of Experimental Hematology, Institute of Hematology & Transfusion Medicine, Warsaw, Poland.
- Tata Memorial Hospital, Mumbai, India.
- Department of Clinical Pharmacology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Shenoy, P. S., Dash, S., Joshi, D., Rekhi, B., Gota, V., & Ray, P. (2025). Withaferin A Exerts Cytotoxicity in Single/Multidrug‐Resistant Gastric and Ovarian Cancer Cells and Tumor Xenografts Through the AKT–NF‐κB–STAT3–Survivin Axis. Molecular Carcinogenesis, 64(12), 2037-2051. https://doi.org/10.1002/mc.70043
Vancouver
Shenoy PS, Dash S, Joshi D, Rekhi B, Gota V, Ray P. Withaferin A Exerts Cytotoxicity in Single/Multidrug‐Resistant Gastric and Ovarian Cancer Cells and Tumor Xenografts Through the AKT–NF‐κB–STAT3–Survivin Axis. Molecular Carcinogenesis. 2025;64(12):2037-2051. doi:10.1002/mc.70043
BibTeX
@article{Shenoy2025,
author = {Shenoy, Priti S and Dash, Shubhankar and Joshi, Diksha and Rekhi, Bharat and Gota, Vikram and Ray, Pritha},
title = {Withaferin A Exerts Cytotoxicity in Single/Multidrug‐Resistant Gastric and Ovarian Cancer Cells and Tumor Xenografts Through the AKT–NF‐κB–STAT3–Survivin Axis},
journal = {Molecular Carcinogenesis},
year = {2025},
volume = {64},
number = {12},
pages = {2037--2051},
doi = {10.1002/mc.70043}
}
EUVIMED